RA
Rosalind Advisors Portfolio holdings
AUM
$274M
1-Year Est. Return
82.13%
This Fund
S&P 500
1 Year Est. Return
+82.13%
AUM
$283M
AUM Growth
+$76.3M
(+37%)
Holding
42
Top Buys
| 1 | +$10.4M | |
| 2 | +$7.48M | |
| 3 | +$6.49M | |
| 4 |
MediWound
MDWD
|
+$6.31M |
| 5 |
HELP
Cybin Inc
HELP
|
+$4.88M |
Top Sells
| 1 | +$9.79M | |
| 2 | +$7.43M | |
| 3 | +$5.75M | |
| 4 |
Pharvaris
PHVS
|
+$3.94M |
| 5 |
IDEAYA Biosciences
IDYA
|
+$3.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Biofrontera
BFRI
$10.6M
| $1.12M | 0.4% |
1,140,764
+164,316
|
|
||
|
ATXS
27
DELISTED
Astria Therapeutics
ATXS
| $1.11M | 0.39% |
+1,542,520
|
|
||
28
Trevi Therapeutics
TRVI
$1.53B
| $915K | 0.32% |
100,000
-200,000
|
|
||
29
Kura Oncology
KURA
$760M
| $885K | 0.31% |
100,000
|
|
||
|
CMPS
30
Compass Pathways
CMPS
$783M
| – | – |
-482,651
|
|
||
31
iShares S&P 100 ETF
OEF
$28.5B
| – | – |
0
|
|
||
32
Ovid Therapeutics
OVID
$116M
| – | – |
-500,000
|
|
||
|
33
Pharvaris
PHVS
$1.84B
| – | – |
-223,627
|
|
||
34
Crinetics Pharmaceuticals
CRNX
$4.21B
| – | – |
0
|
|
||
35
INmune Bio
INMB
$34.3M
| – | – |
0
|
|
||
36
KalVista Pharmaceuticals
KALV
$823M
| – | – |
-157,725
|
|
||
37
Invesco QQQ Trust
QQQ
$397B
| – | – |
0
|
|
||
38
Replimune Group
REPL
$632M
| – | – |
-900,000
|
|
||
39
State Street SPDR S&P 500 ETF Trust
SPY
$699B
| – | – |
0
|
|
||
40
Scholar Rock
SRRK
$4.52B
| – | – |
0
|
|
||
41
UroGen Pharma
URGN
$1.02B
| – | – |
-542,366
|
|
||
42
State Street SPDR NYSE Technology ETF
XNTK
$1.52B
| – | – |
0
|
|